J&J Pays $2.2 Billion in Risperdal Damages
In one of the country’s largest health care-related settlements, pharmaceutical giant Johnson & Johnson paid $2.2 billion to settle charges of false marketing, and paying doctors and nursing homes kickbacks for promoting drugs for unapproved uses.
Officials with the U.S. Department of Justice alleged that Johnson & Johnson promoted the use of Risperdal, a drug approved by the Food and Drug Administration only for the treatment of schizophrenia, for controlling symptoms of anxiety and aggression in elderly dementia patients, as well as in children and the mentally disabled with behavioral problems.
TriMark Legal Funding provides Risperdal pre settlement funding to injured plaintiffs nationwide.
This post originally appeared here: https://www.drugwatch.com/news/2013/11/07/johnson-johnson-settlement-risperdal/
Click here to see the full original article.